Ames Philip, Galor Anat
Miami Veterans Administration Medical Center, 1201 NW 16th St, Miami, FL 33125, USA ; Bascom Palmer Eye Institute, University of Miami, 900 NW 17th Street, Miami, FL 33136, USA.
Clin Investig (Lond). 2015;5(3):267-285. doi: 10.4155/cli.14.135.
Dry eye has gained recognition as a public health problem given its high prevalence, morbidity and cost implications. Although dry eye is common and affects patients' quality of life, only one medication, cyclosporine 0.05% emulsion, has been approved by the US FDA for its treatment. In this review, we summarize the basic science and clinical data regarding the use of cyclosporine in the treatment of dry eye. Randomized controlled trials showed that cyclosporine emulsion outperformed vehicles in the majority of trials, consistently decreasing corneal staining and increasing Schirmer scores. Symptom improvement was more variable, however, with ocular dryness shown to be the most consistently improved symptom over vehicle.
鉴于干眼症的高患病率、发病率及成本影响，它已被视为一个公共卫生问题。尽管干眼症很常见且会影响患者的生活质量，但美国食品药品监督管理局（US FDA）仅批准了一种药物——0.05%环孢素乳剂用于治疗。在本综述中，我们总结了关于使用环孢素治疗干眼症的基础科学和临床数据。随机对照试验表明，在大多数试验中环孢素乳剂的效果优于赋形剂，能持续减少角膜染色并提高泪液分泌试验（Schirmer）评分。然而，症状改善情况的差异更大，其中眼干是相较于赋形剂而言最持续改善的症状。
